Table 1 Baseline characteristics of the patients
Characteristics | Overall (n = 401) | Genotype 1 (n = 315) | Genotype 2 (n = 86 ) |
|---|---|---|---|
Male sex, n (%) | 170 (42.4%) | 132 (41.9%) | 38 (44.2%) |
Age, median years (range) | 67 (22–87) | 68 (31–87) | 65 (22–84) |
Cirrhosis, n (%) | 89 (22.2%) | 75 (23.8%) | 14 (16.3%) |
Treatment experienced, n (%) | 123 (30.7%) | 110 (34.9%) | 13 (15.1%) |
HCV RNA, log IU/mL, median (range) | 6.1 (2.0–7.5) | 6.1 (2.0–7.5) | 5.9 (3.0–7.2) |
Albumin, g/dL, median (range) | 4.1 (2.6–4.9) | 4.1 (2.6–4.9) | 4.1 (2.9–4.8) |
Total bilirubin, mg/dL, median (range) | 0.7 (0.2–28.1) | 0.7 (0.2–28.1) | 0.7 (0.2–2.4) |
AST, IU/L, median (range) | 41 (10–360) | 42 (10–360) | 38 (14–250) |
ALT, IU/L, median (range) | 42 (5–382) | 42 (8–382) | 40 (5–251) |
Platelets, ×104/mm3, median (range) | 14.6 (0.6–55.2) | 14.6 (0.6–55.2) | 14.4 (4.0–30.0) |
Prothrombin time, %, median (range) | 90.0 (16.3–134.2) | 90.3 (20.4–134.2) | 86.9 (16.3–121.1) |
Hemoglobin, g/dL, median (range) | 13.4 (1.1–18.4) | 13.4 (1.1–17.0) | 13.5 (9.1–18.4) |
NS5A resistance associated variantsa, n (%) | |||
Neither L31 or Y93 | – | 184 (58.4%) | – |
Either L31 or Y93 | – | 40 (12.7%) | – |
Both L31 and Y93 | – | 2 (0.6%) | – |
Treatment agents, n (%) | |||
DCV+ASV | 110 (27.4%) | 110 (34.9%) | 0 ( 0%) |
SOF/LDV | 184 (45.9%) | 184 (58.4%) | 0 ( 0%) |
OBV/PTV/r | 10 ( 2.5%) | 10 ( 3.2%) | 0 ( 0%) |
EBR+GZR | 11 ( 2.8%) | 11 ( 3.5%) | 0 ( 0%) |
SOF+RBV | 85 (21.2%) | 0 ( 0%) | 85 (98.8%) |
OBV/PTV/r+RBV | 1 ( 0.2%) | 0 ( 0%) | 1 ( 1.2%) |